GigaGen

company

About

GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$880K
Industries
Biotechnology,Genetics,Medical,Therapeutics
Founded date
Mar 1, 2010
Number Of Employee
11 - 50
Operating Status
Active


GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$880K
GigaGen has raised a total of $880K in funding over 2 rounds. Their latest funding was raised on Aug 31, 2012 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 31, 2012 Grant $880K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
1
1
GigaGen is funded by 1 investors. National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant